drugset / Trial / NCT01745458

SB-659032 Platelet Aggregation Study

NCT01745458 ↗

Phase 1 Completed 26 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

This study is designed to assess whether inhibition of plasma Lp-PLA2 activity impacts platelet function as assessed by ex vivo platelet aggregation tests and in vivo plasma biomarkers.

Timeline

Start
2005-07
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rilapladib Small molecule 250 mg Oral

Indications